Navigation Links
New mechanisms of tumor resistance to targeted therapy in lung cancer are discovered
Date:8/17/2010

Cold Spring Harbor, NY -- One of the most tantalizing developments in anti-cancer therapy over recent years has been the advent of targeted treatments, which have proven highly effective in holding aggressive cancers at bay in certain patients, although typically only for a limited period of time.

A team led by Raffaella Sordella, Ph.D., an Assistant Professor at Cold Spring Harbor Laboratory (CSHL), today published results of a study that suggests new ways in which tumor cells develop resistance to one of the most successful targeted therapies, the small-molecule drug Tarceva (erlotinib). Since its approval by the U.S. Food and Drug Administration in 2004, Tarceva has produced dramatic, albeit impermanent, remissions in a subset of patients with notoriously difficult-to-treat cancers including non-small cell lung cancer (NSCLC) and pancreatic cancer.

Tarceva homes in on a specific area, or domain, of a very common cell-membrane receptor called EGFR, the epidermal growth-factor receptor. The drug has been shown to be effective in some NSCLC patients with specific oncogenic (cancer-promoting) mutations of EGFR. The drug molecule physically occupies a tiny pocket in the receptor structure--within an area called the tyrosine kinase domain, located just beneath the surface of the cell. This prevents the receptor from initiating a cascade of internal signals that can cause cellular growth to careen out of control, something like a switch stuck in the "on" position.

Over recent years Sordella and colleagues have focused on the question of how NSCLC tumor cells develop resistance to Tarceva. Specifically, they wanted to move beyond known explanations accounting for about half of the observed resistance. "Our colleagues in the field have already shown that secondary mutations of EGFR or amplification of a gene called c-MET are responsible for about 50% of cases of Tarceva resistance. We wanted to explain the other cases, in which the mec
'/>"/>

Contact: Peter Tarr
tarr@cshl.edu
516-367-8455
Cold Spring Harbor Laboratory
Source:Eurekalert

Page: 1 2

Related biology news :

1. Corn researchers discover novel gene shut-off mechanisms
2. Mechanisms of cardiovascular disease and cancer give clues to new therapies
3. Neural mechanisms of value bias in the human visual cortex
4. I feel your pain: Neural mechanisms of empathy
5. DNA repair mechanisms relocate in response to stress
6. Disease Models & Mechanisms -- selected for indexing in Medline
7. Researcher garners major award from NIH for further exploration into the mechanisms of obesity
8. UT Southwestern researchers examine mechanisms that help cancer cells proliferate
9. Seeing how evolutionary mechanisms yield biological diversity
10. New research into the mechanisms of gene regulation
11. IUPUI researchers tackle protein mechanisms behind limb regeneration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 /PRNewswire/ ... www.icg-10.org ) se celebrará por medio de BGI del 22 ... China . Este año, la conferencia ... 2006, ICG se ha convertido en una de las reuniones ... de ser una de las reuniones más dinámicas, entusiastas y ...
(Date:7/30/2015)... 2015 Cellecta, Inc., a U.S.-based provider ... and biomarker discovery, announced the release of its ... all human protein coding genes. CRISPR technology enables ... gene,s function. Cellecta,s new Human Whole Genome CRISPR ... so that researchers can investigate in a single ...
(Date:7/23/2015)... , July 23, 2015 Research ... addition of the "Global Outlook of the ... offering. The global biometrics market ... public and commercial applications owing to the uptake ... witness a transformation that enhances the growth of ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... team of Duke Medicine researchers has engineered cartilage from induced ... use in tissue repair and studies into cartilage injury and ... in the journal the Proceedings of the National Academy ... or iPSCs, may be a viable source of patient-specific articular ...
... The Journal of Cell Biology shows how ... nerve cells to help prevent neurodegeneration. The findings could pave ... in patients with neurodegenerative diseases. In Lou Gehrig,s ... in stages, with axons deteriorating first and the cells themselves ...
... who have lost a substantial amount of weight after ... their siblings who were born before the weight loss ... weight loss that occur after the surgery have a ... according to a new study presented at the Canadian ...
Cached Biology News:Duke researchers engineer cartilage from pluripotent stem cells 2Stay-at-home transcription factor prevents neurodegeneration 2Obese moms give birth to heart healthier kids following bariatric surgery 2Obese moms give birth to heart healthier kids following bariatric surgery 3
(Date:8/3/2015)... , Aug. 3, 2015  Merck KGaA, Darmstadt, ... and top-quality high-tech products in the healthcare, life science ... US-based company Nano-C, their development and launch of promising ... photovoltaics (OPV). Merck KGaA, Darmstadt, Germany ... growing OPV sector. Novel derivatives: highly stable, ...
(Date:8/3/2015)... E-QURE Corp. (OTCQB: EQUR), a ... Signal Therapy device ("BST Device"), a new and novel ... chronic wounds, today announced that the Company has signed ... specializing in medical devices, for the marketing and distribution ... 70 years old, sales, marketing and distribution company in ...
(Date:8/3/2015)... BC , Aug. 3, 2015 /PRNewswire/ - RepliCel Life ... medicine company focused on the development of autologous cell therapies, ... be presenting at the InvestMNT conference held in ... 8:15 AM local time. Hall,s presentation will highlight RepliCel,s 18-month ... sale in Europe , clinical data from ...
(Date:7/31/2015)... Texas (PRWEB) , ... July 31, 2015 , ... ... report, offering competitive market analysis and premium industry insights on the global resorcinol ... based on a collective study of vivid market scenarios and analysis of primary ...
Breaking Biology Technology:Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4
... DURHAM, N.C., Dec. 16 Parion Sciences, Inc., ... from the failure of the body,s mucosal defenses, ... have awarded the,company a biodefense grant in excess ... The purpose of the grant is to ...
... KRAS Biomarker PresentsPotential toPersonalize Colorectal Cancer Treatment Determining Who ... , THOUSAND OAKS, Calif., Dec. 16 Amgen ... discuss the clinical utility of the KRAS ... colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor ...
... 16 , - ... The American Journal of Medicine (AJM), one of ... Medicine blog,( http://amjmed.blogspot.com ), a dynamic forum where physicians and ... that have been published in the Journal. , ...
Cached Biology Technology:Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury 2Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury 3Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 2Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 3Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 4Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 5Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 6Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 7Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 8Elsevier Introduces The American Journal of Medicine Blog 2Elsevier Introduces The American Journal of Medicine Blog 3
Rabbit polyclonal to JNK1 (phospho T183 + Y185) ( Abpromise for all tested applications). entrezGeneID: 5599 SwissProtID: P45983...
... Abpromise for all tested applications). ... to KLH derived from within residues 400 ... acid sequence is proprietary)(Peptide available as ... ID: 55693 Swiss ...
Rabbit polyclonal to JAK1 (phospho Y1022 + Y1023) ( Abpromise for all tested applications). entrezGeneID: 3716 SwissProtID: P23458...
Cytofix/Cytoperm Plus Kit with GolgiPlug 250 Tests...
Biology Products: